Abstract
Abstract
Background
Cognitive therapy for social anxiety disorder (CT-SAD) has extensive empirical support and is recommended in several national guidelines. However, ensuring access to evidence-based psychological therapies such as CT-SAD remains a global challenge. An internet-delivered version of this treatment protocol (iCT-SAD) has recently been developed in the UK as a way to overcome this challenge, demonstrating comparable outcomes to face-to-face CT-SAD whilst requiring less therapist time per client. Initial findings also suggest its cross-cultural transferability, but the previous studies in other cultural settings used the English language programme and only included English-fluent participants as a second language. It is not yet known what outcomes can be achieved once the programme has been translated and adapted for a different cultural context. Therefore, this trial aims to evaluate the clinical efficacy of Japanese iCT-SAD when combined with treatment as usual (TAU) in clients with SAD.
Methods
This two-arm, parallel-group, superiority randomised controlled trial will recruit 60 Japanese participants with SAD, randomly assigning them to either Japanese iCT-SAD + TAU or TAU alone at a ratio of 1:1. The primary outcome measure is the self-report Liebowitz Social Anxiety Scale, and secondary.outcomes include other measures of social anxiety symptoms and processes, general mood and functioning, and response to treatment. We will also assess treatment acceptability and gather participant feedback. Assessments will take place at baseline (week 0), mid-treatment (week 8), and post-treatment (week 15), with a further 3-month follow-up (week 27) for the iCT-SAD + TAU arm. The primary analyses will be conducted on an intent-to-treat basis, comparing the primary and secondary outcome measures between groups using linear mixed-effect models, along with additional mediation analysis.
Discussion
Investigating the efficacy of translated and culturally adapted iCT-SAD in different cultural contexts is an important step in evaluating the global reach of internet interventions. This trial will provide valuable insights into the effects of iCT-SAD combined with usual care, and how this treatment could be delivered in routine clinical settings in Japan.
Trial registration
International Standard Randomized Controlled Trials (ISRCTN), ISRCTN82859645, registered on January 19, 2024. UMIN Clinical Trials Registry (UMIN-CTR), UMIN000052702, registered on November 6, 2023.
Funder
Japan Society for the Promotion of Science London
Daiwa Anglo-Japanese Foundation
Wellcome Trust
Oxford Health NIHR Biomedical Research Centre
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Stein MB, Stein DJ. Social anxiety disorder. Lancet (London, England). 2008;371(9618):1115–25. https://doi.org/10.1016/S0140-6736(08)60488-2.
2. Clark DM, Wells A. A cognitive model of social phobia. Social phobia: Diagnosis, assessment, and treatment. New York: The Guilford Press; 1995. p. 69–93.
3. Mayo-Wilson E, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368–76. https://doi.org/10.1016/S2215-0366(14)70329-3.
4. National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment. Clinical guideline CG159. 2013. https://www.nice.org.uk/guidance/cg159. Accessed 22 Aug 2023.
5. Asakura S, Yoshinaga N, Yamada H, Fujii Y, Mitsui N, Kanai Y, Inoue T, Shimizu E. Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: clinical practice guideline for social anxiety disorder (2021). Neuropsychopharmacol Rep. 2023;43(3):289–310. https://doi.org/10.1002/npr2.12365.